Cambridge biotech opts for Nasdaq listing over LSE’s AIM

Life sciences research tool supplier Abcam said it will seek to delist from the AIM on London’s stock exchange following a “positive shareholder response”.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.